Women with high levels of antibodies related to celiac disease are more likely to deliver low birthweight (LBW) babies, according to a large Belgian study published in Gastroenterology.
Women with high levels of antibodies related to celiac disease are more likely to deliver low birthweight (LBW) babies, according to a large Belgian study published in Gastroenterology.
The findings, by researchers from Erasmus University Medical Center, Rotterdam, were based on analysis of levels of anti-tissue transglutaminase (anti-tTG) in second-trimester serum samples. The antibodies are a marker of celiac disease and the cohort for the population-based prospective study was a group of 7,046 pregnant women.
Among the participants, 6,702 were considered negative for anti-tTG (≤0.79 U/mL), 308 had intermediate levels (0.8 to ≤6 U/mL) of the antibody, and 36 were positive (>6 U/mL) for anti-tTG. Ultrasound measurements and medical records were the source of data on fetal growth and birth outcome in the cohort.
During the second trimester, fetuses of women who were positive for anti-tTG weighed 16 g less than those of women who were negative (95% CI, -32 to -1g). The difference was larger in the third trimester: 74 g (95% CI, -140 to -8 g). A similar trend was seen in birthweights, with newborns of women in the intermediate and positive anti-tTG groups weighing 53 g (95% CI, -106 to -1g) and 159 g (95% CI, -316 to -1 g) less, respectively, than those of women in the anti-tTG group.
The researchers concluded that levels of anti-tTG in pregnant women are inversely associated with fetal growth, with the greatest growth reduction seen in fetuses of women with the highest levels of anti-tTG. Birthweight was also reduced in women with intermediate levels of anti-tTG. Said lead author Jessica Kiefte-de Jong, MSc, “Researchers need to explore the natural history and long-term consequences of intermediate anti-tTG levels to determine if these levels are caused by pregnancy or whether it reflects a subclinical state of celiac disease that needs follow-up.”
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More